✦ LIBER ✦

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05)

✍ Scribed by Joerger, M.; Baty, F.; Früh, M.; Droege, C.; Stahel, R.A.; Betticher, D.C.; von Moos, R.; Ochsenbein, A.; Pless, M.; Gautschi, O.; Rothschild, S.; Brauchli, P.; Klingbiel, D.; Zappa, F.; Brutsche, M.

Book ID: 124111083
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 663 KB
Volume: 85
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2014.04.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

25PD CIRCULATING MICRO-RNA PROFILING IN

25PD CIRCULATING MICRO-RNA PROFILING IN PATIENTS WITH ADVANCED NON-SQUAMOUS NON SMALL-CELL LUNG CANCER RECEIVING BEVACIZUMAB/ERLOTINIB FIRST-LINE TREATMENT FOLLOWED BY PLATINUM-BASED CHEMOTHERAPY AT DISEASE PROGRESSION (SAKK 19/05)

✍ Joerger, M.; Baty, F.; Stahel, R.A.; Betticher, D.; von Moos, R.; Pless, M.; Gau 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 46 KB

Bevacizumab and erlotinib (BE) first-lin

Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: A multicenter phase II trial (SAKK 19/05)

✍ Zappa, Francesco; Droege, Cornelia; Betticher, Daniel; von Moos, Roger; Bubendor 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 325 KB

9147 Bevacizumab and erlotinib as first-

9147 Bevacizumab and erlotinib as first-line therapy in advanced (stage IIIB/IV) non-squamous non-small-cell lung cancer (NSCLC) followed by platinum-based chemotherapy (CT) at disease progression – a multicenter phase II trial of SAKK

✍ Zappa, F.; Droege, C.; Betticher, D.; von Moos, R.; Ochsenbein, A.; Stahel, R.; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB